Julia Lopez MP: written questions 2025
75 published records · newest first.
Written questions
Trade Agreements: USADepartment for Business and TradeTabled 12 Dec 2025AnsweredUIN 99524More
Question: To ask the Secretary of State for Business and Trade, if he will publish the full legal texts establishing the MFN mitigations with the US.
Answer: The UK has secured a zero percent tariff on all pharmaceuticals exported to the US - the lowest rate offered to any country. We have also secured preferential terms for the UK’s medical technology exports for three years, meaning no additional new tariffs...
Answered 17 Dec 2025
Original Parliament recordDrugs: USADepartment for Business and TradeTabled 12 Dec 2025AnsweredUIN 99523More
Question: To ask the Secretary of State for Business and Trade, pursuant to the answer of 10 December 2025 to Question 97685, whether any additional commitments have been made by the UK in relation to UK-US agreement on pharmaceutical in addition to the increased s
Answer: The UK has secured a zero percent tariff on all pharmaceuticals exported to the US - the lowest rate offered to any country. We have also secured preferential terms for the UK’s medical technology exports for three years, meaning no additional new tariffs...
Answered 17 Dec 2025
Original Parliament recordDrugs: USADepartment for Business and TradeTabled 12 Dec 2025AnsweredUIN 99522More
Question: To ask the Secretary of State for Business and Trade, pursuant to the answer of 9 December 2025 to Question 97256, what his planned timeframe is for the further work to finalise underpinning details to be completed.
Answer: The UK has secured a zero percent tariff on all pharmaceuticals exported to the US - the lowest rate offered to any country. We have also secured preferential terms for the UK’s medical technology exports for three years, meaning no additional new tariffs...
Answered 17 Dec 2025
Original Parliament recordNHS: DrugsDepartment of Health and Social CareTabled 10 Dec 2025AnsweredUIN 98909More
Question: To ask the Secretary of State for Health and Social Care, whether the UK is (a) excluded from, (b) partially exempted from and (c) otherwise subject to special treatment under the United States’ Most Favoured Nation drug pricing policy.
Answer: Thanks to strong United Kingdom support for innovation, the UK has secured mitigations under the United States’ ‘Most Favoured Nation’ drug pricing initiative so that we will continue to ensure access to the latest treatments. This will encourage pharmace...
Answered 17 Dec 2025
Original Parliament recordTelecommunications: InfrastructureDepartment for Science, Innovation and TechnologyTabled 10 Dec 2025AnsweredUIN 98906More
Question: To ask the Secretary of State for Science, Innovation and Technology, whether it is still her Department’s policy to finalise s61-64 of the Product Security and Telecommunications Infrastructure Act 2022, relating to renewal agreements, by the end of 2025
Answer: As per the commitment made in the Written Ministerial Statement on 21 July 2025, on 15 December 2025 the Department made regulations implementing Sections 61 – 64 of the Product Security and Telecommunications Infrastructure Act 2022 and published its res...
Answered 18 Dec 2025
Original Parliament recordTelecommunications: InfrastructureDepartment for Science, Innovation and TechnologyTabled 10 Dec 2025AnsweredUIN 98905More
Question: To ask the Secretary of State for Science, Innovation and Technology, when she plans to publish her Department's response to the consultation entitled Draft regulations to commence Sections 61 to 64 of the Product Security and Telecommunications Infrastru
Answer: As per the commitment made in the Written Ministerial Statement on 21 July 2025, on 15 December 2025 the Department made regulations implementing Sections 61 – 64 of the Product Security and Telecommunications Infrastructure Act 2022 and published its res...
Answered 18 Dec 2025
Original Parliament recordDrugs: USADepartment for Business and TradeTabled 5 Dec 2025AnsweredUIN 97685More
Question: To ask the Secretary of State for Business and Trade, with reference to the US Trade Representative's press release entitled U.S. Government Announces Agreement in Principle with the United Kingdom on Pharmaceutical Pricing, published on 1 December 2025,
Answer: As set out by the Secretary of State in his written statement to Parliament on 2 December, we have secured a zero percent tariff on all pharmaceuticals exported to the US - the lowest rate offered to any country. The UK has also secured preferential terms...
Answered 10 Dec 2025
Original Parliament recordNHS: DrugsDepartment of Health and Social CareTabled 5 Dec 2025AnsweredUIN 97665More
Question: To ask the Secretary of State for Health and Social Care, whether the capped VPAG rate referred to in the UK-US Economic Prosperity Deal will only apply to pharmaceutical products of US origin.
Answer: The capped rate applies to all newer medicines, not just pharmaceutical products originating from the United States.
Answered 17 Dec 2025
Original Parliament recordDrugs: USADepartment for Business and TradeTabled 5 Dec 2025AnsweredUIN 97663More
Question: To ask the Secretary of State for Business and Trade, what mechanisms within the UK-US Economic Prosperity Deal will ensure that pharmaceutical products launched in the UK with a lower price than in the US will not trigger Most Favoured Nation rebates.
Answer: We have secured the first and only deal with the US that delivers zero percent tariffs on pharmaceutical products – the lowest rate offered to any country. It delivers mitigations on the US’ ‘Most Favoured Nation’ policy and preferential terms for UK medt...
Answered 10 Dec 2025
Original Parliament recordDrugs: USADepartment for Business and TradeTabled 4 Dec 2025AnsweredUIN 97256More
Question: To ask the Secretary of State for Business and Trade, what legal instrument establishes Most Favoured Nation mitigations in the deal with the US on pharmaceuticals.
Answer: We have secured the first and only deal with the US that delivers zero percent tariffs on pharmaceutical products – the lowest rate offered to any country.It delivers mitigations on the US’ ‘Most Favoured Nation’ policy and preferential terms for UK medte...
Answered 9 Dec 2025
Original Parliament recordDrugs: USADepartment for Business and TradeTabled 4 Dec 2025AnsweredUIN 97255More
Question: To ask the Secretary of State for Business and Trade, what the mitigations are under the US Most Favoured Nation drug pricing initiative as referred to in the UK-US Economic Prosperity Deal.
Answer: The US has committed to ensuring that access to medicines and launches of new innovative medicines in the UK are not inadvertently impacted by the US’s ‘Most Favoured Nation’ policy, thereby reducing the risk to the UK where the NHS has managed to secure ...
Answered 9 Dec 2025
Original Parliament recordDrugs: USADepartment for Business and TradeTabled 4 Dec 2025AnsweredUIN 97254More
Question: To ask the Secretary of State for Business and Trade, which Department is responsible for monitoring of pharmaceutical provisions within the UK-US Economic Prosperity Deal; and whether he plans to update Parliament on those provisions.
Answer: DBT Secretary of State made a written statement to Parliament on 2 December.This deal is the first and only agreement with the US that secures zero percent tariffs on pharmaceutical products – the lowest rate offered to any country. It delivers mitigation...
Answered 9 Dec 2025
Original Parliament recordNHS: DrugsDepartment of Health and Social CareTabled 4 Dec 2025AnsweredUIN 97253More
Question: To ask the Secretary of State for Health and Social Care, from which Department’s budget the additional NHS medicines spend following the UK-US Economic Prosperity Deal will be funded.
Answer: Every patient deserves access to the best possible treatment. This deal is a vital investment that builds on the strength of our National Health Service and world leading life sciences sector.Costs will start smaller but will increase over time as the Nat...
Answered 17 Dec 2025
Original Parliament recordNHS: DrugsDepartment of Health and Social CareTabled 4 Dec 2025AnsweredUIN 97252More
Question: To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the 25% net increase in prices for new medicines and the 15% VPAG repayment cap on annual NHS medicines spend.
Answer: Every patient deserves access to the best possible treatment. This deal is a vital investment that builds on the strength of our National Health Service and world leading life sciences sector.Costs will start smaller but will increase over time as the Nat...
Answered 17 Dec 2025
Original Parliament recordDigital Service ProvidersDepartment for Business and TradeTabled 25 Nov 2025AnsweredUIN 94367More
Question: To ask the Secretary of State for Business and Trade, what steps his Department is taking to increase interoperability and competitiveness in the domestic cloud market following recent widespread outages caused by dominant providers in the industry.
Answer: In July 2025, the Competition and Markets Authority (CMA) published its final report on the UK cloud market. The key recommendation was for the CMA Board to prioritise commencing investigations under the digital markets regime and to consider designating ...
Answered 1 Dec 2025
Original Parliament recordInternet: OutagesTreasuryTabled 25 Nov 2025AnsweredUIN 94366More
Question: To ask the Chancellor of the Exchequer, what estimate her Department has made of the cost to the economy of recent outages of large-scale cloud providers.
Answer: I refer the member to the answer given to UIN 92928 on 24 November 2025.
Answered 1 Dec 2025
Original Parliament recordDigital Service Providers: CompetitionDepartment for Science, Innovation and TechnologyTabled 25 Nov 2025AnsweredUIN 94365More
Question: To ask the Secretary of State for Science, Innovation and Technology, what assessment her Department has made of the level of systemic risk from reliance on two dominant cloud providers following recent outages.
Answer: I refer the honourable member to the answer given on 24 November to UIN 92927. The Department for Science, Innovation and Technology (DSIT) continues to monitor systemic risks to UK critical national infrastructure from reliance on cloud providers, includ...
Answered 2 Dec 2025
Original Parliament recordDigital Service Providers: CompetitionDepartment for Science, Innovation and TechnologyTabled 25 Nov 2025AnsweredUIN 94364More
Question: To ask the Secretary of State for Science, Innovation and Technology, what steps she is taking to help ease restrictive licensing practices in relation to software by large cloud providers to ensure that there is fair and open competition in the sector.
Answer: The Government is committed to supporting a competitive and innovative digital economy. This is why we prioritised the commencement and implementation of the Competition and Markets Authority’s (the CMA) new powers in digital markets. The CMA is independe...
Answered 2 Dec 2025
Original Parliament recordDigital Service Providers: CompetitionDepartment for Science, Innovation and TechnologyTabled 25 Nov 2025AnsweredUIN 94363More
Question: To ask the Secretary of State for Science, Innovation and Technology, what steps her Department is taking to help accelerate the process to designate cloud services with Digital Market Unit's Strategic Market Status to prevent anti-competitive practices i
Answer: The Competition and Markets Authority (the CMA) has completed three Strategic Market Status investigations this year. The CMA is independent of the Government and decisions on which markets to investigate are for its Board. The CMA has published guidance ...
Answered 2 Dec 2025
Original Parliament recordVisual Impairment: RehabilitationDepartment of Health and Social CareTabled 25 Nov 2025AnsweredUIN 94360More
Question: To ask the Secretary of State for Health and Social Care, what steps his Department is taking to secure a sustainable future for the vision rehabilitation workforce.
Answer: We are progressing towards a National Care Service, and this includes expanding career opportunities through the Care Workforce Pathway, and investing £12 million in learning, development, and new qualifications. The Level 2 Adult Social Care Certificate ...
Answered 2 Dec 2025
Original Parliament recordVisual Impairment: RehabilitationDepartment of Health and Social CareTabled 25 Nov 2025AnsweredUIN 94359More
Question: To ask the Secretary of State for Health and Social Care, what assessment his Department has made of (a) the effect of no national oversight relating to the quality of vision rehabilitation services for patients in England and (b) the experiences of those
Answer: Under the Care Act 2014, local authorities have the duty to shape their care market and to commission a range of high-quality, sustainable, and person-centred care and support services to meet the diverse needs of all local people. This includes encouragi...
Answered 2 Dec 2025
Original Parliament recordVisual Impairment: RehabilitationDepartment of Health and Social CareTabled 25 Nov 2025AnsweredUIN 94358More
Question: To ask the Secretary of State for Health and Social Care, if he will make an assessment of recent trends in the number of patients receiving timely access to vision rehabilitation services in line with industry best practice.
Answer: The Care Quality Commission (CQC) is now assessing how local authorities are meeting the full range of their duties under Part 1 of the Care Act 2014. These assessments identify local authorities’ strengths and areas for development, facilitating the shar...
Answered 2 Dec 2025
Original Parliament recordDrugs: VATTreasuryTabled 3 Nov 2025AnsweredUIN 87680More
Question: To ask the Chancellor of the Exchequer, whether she has made an assessment of the potential impact of introducing VAT to to medicines provided free under Early Access Medicines Scheme programmes on pharmaceutical companies.
Answer: I refer the honourable member to the answer that I gave to PQ UIN: 87051.
Answered 11 Nov 2025
Original Parliament recordDrugs: VATTreasuryTabled 31 Oct 2025AnsweredUIN 87052More
Question: To ask the Chancellor of the Exchequer, what assessment her (a) Department and (b) HMRC have conducted on the potential impact on clinical trial numbers from the introduction of VAT to medicines provided free under Early Access Medicines Scheme programmes
Answer: VAT is the UK’s second largest tax, forecast to raise £180 billion in 2025/26. Taxation is a vital source of revenue which helps to fund public services. Early Access to Medicines Scheme (EAMS) allows patients access to free medicines for life threatening...
Answered 5 Nov 2025
Original Parliament recordDrugs: VATTreasuryTabled 31 Oct 2025AnsweredUIN 87051More
Question: To ask the Chancellor of the Exchequer, what assessment (a) her Department and (b) HMRC have conducted on the potential impact on patient access to innovative medicines from the introduction of VAT to medicines provided free under Early Access Medicines S
Answer: VAT is the UK’s second largest tax, forecast to raise £180 billion in 2025/26. Taxation is a vital source of revenue which helps to fund public services. Early Access to Medicines Scheme (EAMS) allows patients access to free medicines for life threatening...
Answered 5 Nov 2025
Original Parliament record
Published records only — not a full account of an MP’s work. How we work →